Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc.

U.S.-based biotechnology company Biogen ($BIIB) announced plans to acquire private biotech firm RayThera in a deal worth up to $1 billion, adding s...

Biogen to Acquire RayThera in an Up to $1B Deal to Expand Drug Pipeline

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB) and Palvella Therapeutics (PVLA) with ...

Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA)

Analysts are intrested in these 5 stocks: ( ($TVRD) ), ( ($BIIB) ), ( ($FCEL) ), ( ($MGNI) ) and ( ($CDNAF) ). Here is a breakdown of their recent


Tvardi, Biogen, FuelCell, Magnite, Canadian Tire Trending

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Dianthus Therapeutics (DNTH) and Biogen (BIIB) with ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Biogen ( ($BIIB) ) has issued an announcement. On June 9, 2026, Biogen Inc. held its 2026 Annual Meeting of Stockholders, where shareholders electe...

Biogen Shareholders Back Board, Auditor and Pay Policies

Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Biogen Readies New SMA Study After Gene Therapy: What Investors Should Kno...

Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long‑Term Growth

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Savara (SVRA) and Biogen (BIIB) with bullish sentime...

Analysts Offer Insights on Healthcare Companies: Savara (SVRA) and Biogen (BIIB)

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen, with a price target of $227.00. Abrahams covers the ...

RBC Capital Reaffirms Their Buy Rating on Biogen (BIIB)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN), Twist Bioscience (TW...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biogen (BIIB) and Bicara Therapeutics Inc. (BCAX) wi...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BIIB	$196.58	-1.05%	1.73M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BIIB	$196.58	-1.1%	1.73M
3
4
5
6

BIIB

BIIB

No Data Available

Get Biogen Inc. Data in Excel

Get Biogen Inc. Data in Excel